Señales en vivo de FOLD | Maximiza tus Ganancias con Getagraph.com

COMPRAR 116889 min ago

@ $13.20

Emitido: 14 feb 2024 @ 15:36

Retorno: -21.21%

Señal anterior: feb 14 - 09:30

Señal anterior: Vender

Retorno: 1.62 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	1.38M
Volumen promedio	3.06M
Capitalización de mercado	3.08B
EPS	$0 ( 2024-02-28 )
Próxima fecha de ganancias	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.39
ATR14	$0.00900 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Campbell Bradley L	Buy	7 500	Common Stock
2024-05-01	Campbell Bradley L	Sell	7 500	Common Stock
2024-05-01	Campbell Bradley L	Sell	7 500	Stock Options (right to buy)
2024-04-15	Prout Samantha	Sell	7 027	Common Stock
2024-04-01	Campbell Bradley L	Buy	7 500	Common Stock

INSIDER POWER
17.18
Last 100 transactions
Buy: 1 721 174 \| Sell: 1 181 964

Volumen Correlación

Largo: -0.29 (neutral)

Corto: -0.97 (very strong negative)

Signal:(44.39) Neutral

Amicus Therapeutics Inc Correlación

10 Correlaciones Más Positivas
SHLS	0.913
NVEE	0.903
SHC	0.899
MLCO	0.898
FULC	0.898
ALGT	0.894
SIBN	0.893
ARKO	0.887
MLTX	0.886
LPRO	0.88

10 Correlaciones Más Negativas
HZNP	-0.851
TLMD	-0.848
RXDX	-0.845
KNTK	-0.842
TRMR	-0.838
VITL	-0.837
STAA	-0.837
ENTX	-0.837
AEYE	-0.835
VTVT	-0.834

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amicus Therapeutics Inc Correlación - Moneda/Commodity

0.62
( weak )

0.51
( weak )

0.00
( neutral )

0.88
( strong )

-0.71
( moderate negative )

Amicus Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$399.36M
Beneficio Bruto:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2023
Ingresos:	$399.36M
Beneficio Bruto:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2022
Ingresos:	$329.23M
Beneficio Bruto:	$290.63M (88.28 %)
EPS:	$-0.820

FY	2021
Ingresos:	$305.51M
Beneficio Bruto:	$271.05M (88.72 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Actualizaciones en tiempo real para Amicus Therapeutics Inc [FOLD]

Upcoming Earnings Alert